Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hill scrutinizes genetic testing firms

This article was originally published in The Gray Sheet

Executive Summary

House Energy and Commerce Committee is investigating three firms that market personalized genetic testing directly to consumers following a high-profile announcement and reversal by Pathway Genomics earlier this month on plans to start selling its test collection kits at Walgreens retail outlets. Bipartisan leaders of the committee sent letters May 19 to 1Pathway, 223andMe and 3Navigenics, each of which sell genetic test sampling kits and testing services via the Internet, requesting documentation in support of the accuracy of the testing services, of sufficient staff training, of appropriate procedures for providing results to patients and handling DNA samples, and of compliance with FDA regulations. Walgreens delayed plans to carry Pathway's sampling kits after FDA made a public case that the firm was bucking agency regulations by offering the kits and services without approval (4"The Gray Sheet" May 17, 2010)

You may also be interested in...



FDA Cites Long-Term Precedent In Blocking Retail Genetic Screening Plans

A particularly public preemptive stance by FDA's in vitro diagnostics oversight office halted Pathway Genomics' plans last week to start selling genetic screening test sample collection kits out of Walgreens stores, but the office's director stresses the move does not signal any changes to its enforcement policy for laboratory-developed tests

Bridge Too Far? BMS Launch Plan For Sotyktu Pressured By Prospect Of Medicare Price Controls

With price controls in Medicare looming nine years after approval, launch strategies such as ‘bridge’ programs that build initial volume with free drug may have to be adjusted.

Are Regulators Ready For The Robot Era? ChatGPT Weighs In On EU Regulation

Artificial intelligence model’s comments signal the likely start of computer-generated comments to the US FDA’s public notices.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028914

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel